Nicolas Signolle

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 370 citations · Full text

Medicine, Oncology, Pharmacology +17

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

Stéphanie Corgnac, Ines Malenica, Laura Mezquita et al. · Cell Reports Medicine · 2020 · 194 citations · Full text

Life Sciences, Immunology, Oncology +17

<i>Escherichia coli</i> –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Anne‐Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva et al. · Cancer Discovery · 2022 · 76 citations · Full text

Medicine, Immunology, Oncology +17

LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

M.F. Mosele, Amélie Lusque, Véronique Dièras et al. · Annals of Oncology · 2022 · 48 citations

Medicine, Oncology, Pharmacology +17

TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy

Pauline Hamon, Marine Gerbé de Thoré, Marion Classe et al. · Journal for ImmunoTherapy of Cancer · 2022 · 43 citations · Full text

Medicine, Immunology, Oncology +17